One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Key Points

• To evaluate the real-world outcomes of switching to Aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD).
• Analyzed eyes previously treated for nAMD
• Evaluated anatomical improvements after switching to Afl 8 mg
• Assessed treatment intervals post-switch
• Significant anatomical improvement observed in the majority of patients
• Longer treatment intervals achieved after switching
• No new or unexpected safety issues reported